Skip to content
RUO Report
ResearchReviewsPeptidesMethodologyAbout

AOD-9604

Also: hGH fragment 176-191, HGH Frag 176-191, AOD9604, Tyr-hGH(177-191)

Growth Hormone-Derived Peptide FragmentLimitedPrimarily preclinical. The compound has been examined in in-vitro and animal models, chiefly in the context of lipid metabolism, with some exploratory work in cartilage and joint biology. Early-phase human studies reported in the literature for the originally proposed anti-obesity indication did not establish efficacy. Findings should be interpreted cautiously and separated by model type (human vs. animal vs. in-vitro vs. mechanistic).

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

AOD-9604 is a synthetic peptide based on the C-terminal fragment (residues 176-191) of human growth hormone, originally investigated in the research literature as a candidate anti-obesity compound. Most available evidence comes from preclinical in-vitro and animal studies examining lipid metabolism, and early-phase human studies reported in the literature did not establish meaningful efficacy for the originally proposed indication. It is discussed here strictly for research and educational reference; this profile makes no claims about safety, effectiveness, or suitability for any use. Terminology, sequence descriptions, and characterization vary between sources and require editorial and source verification.

Mechanism as described in the literature

AOD-9604 is described in the research literature as a synthetic peptide derived from the C-terminal region of human growth hormone (the hGH 176-191 fragment, with an added tyrosine residue). It is reported to retain part of the lipid-metabolism-associated domain of growth hormone while, in some preclinical work, not reproducing growth hormone's broader effects on IGF-1 or blood glucose. It is not a growth hormone secretagogue and is not described as raising endogenous growth hormone levels.

Mechanistic descriptions are drawn largely from in-vitro and animal models, where the fragment has been examined in the context of lipolysis and lipogenesis in adipose tissue, with some proposed involvement of beta-adrenergic signaling pathways. These mechanisms are characterized at a preclinical level and their relevance to humans is not established; the evidence is limited and requires careful interpretation due to study design and translation limitations.

Research areas

  • Lipid metabolism and lipolysis in preclinical (in-vitro and animal) models
  • Energy balance and metabolic regulation (preclinical/mechanistic)
  • Cartilage and joint biology, including osteoarthritis models (exploratory preclinical research)
  • Comparative analysis versus intact growth hormone signaling (mechanistic)
  • Analytical characterization and anti-doping detection methodology

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is AOD-9604?+

AOD-9604 is a synthetic peptide based on the C-terminal 176-191 fragment of human growth hormone. It has been studied primarily in preclinical research settings and is discussed here for educational and research-reference purposes only, without any claims about its use.

Is AOD-9604 the same as growth hormone?+

No. It is a small fragment derived from one region of the growth hormone molecule. In reported preclinical work it does not reproduce growth hormone's broader signaling effects, and it is not described as a growth hormone secretagogue. Comparisons require careful, source-verified interpretation.

What does the current evidence show?+

The available literature is largely preclinical, and early human studies reported for the originally proposed indication did not establish efficacy. Evidence is limited and should be interpreted cautiously; RUO Report makes no claims about safety or effectiveness.